Limited options exist for patients experiencing a local recurrence of vulvar malignancies after surgery and pelvic radiation. These recurrences often are associated with cancer-related skin desquamation and poor clinical outcomes. A new radiotherapeutic treatment modality for the previously irradiated patient is cyberknife radiosurgery, which uses a linear accelerator mounted on an industrial robotic arm to allow non-coplanar radiation therapy delivery with sub-millimeter precision. This study describes the first reported use of cyberknife radiosurgery for the treatment of recurrent vulvar cancer in three women.
Introduction
Primary carcinoma of the vulva accounts for an estimated 3,490 newly diagnosed cancers in women of the United States, and an estimated 880 women are projected to die of vulvar-cancer related disease (1). Vulvectomy with inguinofemoral lymphadenectomy has been the primary treatment modality with radiation therapy having an established role in the adjuvant lymph node positive and locally advanced settings (2-6). An estimated 11 percent of women relapse when vulvar cancers are initially amenable to surgery, most often when surgicopathological margins are less than eight millimeters (4, 7-9). Local relapse occurs in approximately 25 percent of women treated with radiation therapy and vulvectomy for locally advanced disease (5, 6) . For either a primary or secondary vulvar malignancy, patients commonly present with a palpable labial mass and pruritus but also can experience vulvar pain, postmenopausal or postcoital bleeding, malodorous discharge, dysuria, and ulceration. While the vast majority of women with a recurrent vulvar malignancy are amenable to surgery, age and co-morbid disease may hinder operative management of relapsed disease. For relapsed inoperable patients whom have undergone prior radiation therapy for lymph node positive or locally advanced disease, management strategies are even more restricted due to excessive acute and late toxicity from re-irradiation. Protracted bothersome morbidity from local vulvar cancer relapse necessitates investigation of novel therapeutic alternatives.
Radiosurgery uses image-guided, high dose radiation to clinical targets that may result in a more durable response of vulvar malignancies in women whose tumor is not amenable to surgery and whom have already undergone pelvic radiation.
Technology in Cancer Research & Treatment, Volume 7, Number 5, October 2008 Cyberknife radiosurgery involves delivery in single or hypofractioned high radiation dose with sub-millimeter accuracy using multiple non-coplanar collimated beams generated by a linear accelerator mounted on a computer-driven robotic arm ( Fig. 1 ) (10-13). We report the first published cases of the use of cyberknife radiosurgery for recurrent vulvar malignancies.
Materials and Methods

Cyberknife Radiosurgery
From September 2007 to November 2007, three women older than 85 years underwent cyberknife radiosurgery for inoperable histologically-confirmed squamous cell carcinoma of the vulva at University Hospitals of Cleveland (Cleveland, Ohio). All three women had received prior pelvic radiation for vulvar cancer or other pelvic malignancy. With institutional review board approval, we undertook a retrospective comparative analysis of cyberknife radiosurgery treatment.
After consultation discussing surgical and non-surgical palliative treatment strategies, all three patients elected and consented to cyberknife radiosurgery. Under conscious anxiolysis, patients underwent operative placement of six single 1.6 × 3 mm gold soft tissue markers around the targeted recurrent vulvar cancer nodule. Markers were placed at varying tissue depths separated by two centimeters or more such that intraoperative fluoroscopic images acquired 45 degrees angled to the patient confirmed non-coplanar soft tissue marker placement within a ten centimeter field of view around the target lesion. One week after marker positioning, patients underwent computed tomography planning with two-pin localizing, vacuum-bag pelvic immobilization. With patients in the supine treatment position, contiguous axial computed tomography high-resolution images (1 to 1 pitch, 1.0 mm slice thickness, voltage 120 kVp, 450 mA, 1000 ms) were acquired for inverse radiation treatment planning on the Accuray Treatment Planning System (Accuray, Sunnyvale, California). For treatment planning, both a radiation oncologist and gynecologic oncologist contoured the targeted vulvar tumor and other at-risk tissue designating this contoured volume as the clinical target volume. Normal tissues such as the small bowel, rectum, bladder, bilateral proximal femurs, vagina, and sacral nerve roots were contoured also. With small variation and using 6MV photons, a radiation dose of 3 × 800 cGy = 2400 cGy was selected to deliver a 200 cGy biological equivalent dose greater than 4500 cGy assuming an α/β ratio of 10 for tumor. During radiosurgery delivery, soft tissue fiducial markers were tracked by cross-plane radiographic imaging and confirmed to be in the expected target location in each patient. For soft tissue masses in the vulva, six dimensional tracking (x, y, z, pitch, roll, and yaw) of the fiducial markers was not always possible due to uncertainties associated with marker migration or target volume deformity. In these cases, three dimensional tracking of the target provides for millimeter accuracy of the target center, which is continually updated by the radiographic imaging (approximately 30 times for each fraction). After treatment, patients were seen for follow-up at two and four weeks and every three months thereafter or on an as-needed basis.
Case Reports
Case 1: A 92-year old gravida 3, para 3 female with co-morbid cardiovascular disease and chronic stool incontinence initially underwent vulvectomy and bilateral inguinofemoral lymphadenectomy in April 1999 for a Stage II (T2N0M0) 3 × 1.5 cm pruritic left labia majora exophytic mass. Pathology confirmed an invasive squamous cell carcinoma of the vulva with tumor-free margins of 20 mm and no groin lymph node metastases (0 of 35). In November 2004, she developed a recurrent pruritic 2 × 1.5 cm lesion of the left labia majora. Staging chest radiograph and computed tomography scans of the abdomen and pelvis demonstrated an irregular mass of the vulva not associated with inguinal lymph nodes or other visceral metastases. She underwent wide local excision with 10 mm tumor-free margins. After 18 months of clinical observation, she developed a 2 × 2 cm fungating lesion of the left labia majora. Given her advanced age, co-morbidities, and her desire for conservative management, she underwent enface electron radiation therapy to the left perineum. She received 1760 cGy in eight fractions and 1700 cGy in 10 fractions for a total dose of 3460 cGy. Secondary to radiation-related moist desquamation and risk for sepsis from her chronic stool incontinence, radiation therapy was stopped after 18 fractions. Nine months after her electron radiation therapy, she developed a posterior forchette relapse measuring 3 × 3 cm. Following her desire for conservative non-surgical management, she underwent palliative photon radiation to pelvis to a total dose of 4000 cGy in 20 fractions. Afterwards, her total radiation dose to the left vulva and perineum was 7460 cGy.
Five months after completion of her second course of radiation, physical examination revealed a 1 × 1 cm raised, rounded mass lesion of the posterior left labial fold. Biopsy confirmed recurrent invasive squamous cell carcinoma and staging positron emission and computed tomography scans identified no visceral metastases. She underwent cyberknife radiosurgery treatment to the left labial fold lesion in the supine treatment position. A tumor volume of 34.7 cm 3 was planned to receive 2400 cGy in three fractions of 800 cGy prescribed to the 70 percent isodose line with a conformality index of 1.9 to achieve 98.9 percent coverage. To deliver therapy, 205 non-coplanar 6MV photon beams shaped by a 25 mm collimator were used with source to axis distance ranging between 900 and 1000 millimeters. Elapsed treatment time for each fraction was approximately 42 minutes. Accounting for pretreatment and fiducial-tracking adjustments, her total estimated treatment delivery time was 87 minutes. During her fractionated radiosurgical treatment course, no significant skin, urinary, or gastrointestinal toxicities were encountered.
At two-and four-week follow-up, pelvic examination showed hypopigmentation of the perineal skin associated with a pruritic half-centimeter necrotic mass within the radiosurgical field. Close supervision was continued with recommendations for aggressive pelvic hygiene with aloecontaining emollient skin barrier due to her chronic stool incontinence. At three-month follow-up, noted was a halfcentimeter sized rectovaginal fistula with no visible tumor approximating the site of her cyberknife radiosurgery. Also noted at the three-month follow-up visit was a second area of tumor not present at the time of radiosurgery. Biopsy of this left labial tumor outside the radiosurgical field confirmed an area of recurrent squamous cell carcinoma of the vulva. She has elected palliative supportive care at a nursing facility and remains alive. She desired non-surgical treatment, refused conventional 6-week course of conformal radiotherapy, and elected to undergo cyberknife radiosurgery in the supine treatment position. The right labia majora tumor volume of 24.7 cm 3 received 2400 cGy in three fractions of 800 cGy prescribed to the 75 percent isodose line with a conformality index of 1.6 to achieve 95.5 percent coverage. Each fraction used 213 non-coplanar 6MV photon beams shaped by a 25 mm collimator and a source to axis distance ranging between 900 and 1000 millimeters. Elapsed treatment time was approximately 46 minutes and total estimated treatment delivery time was 92 minutes for each fraction. No skin, urinary, or gastrointestinal toxicities were observed during her fractionated radiosurgical course.
Two-and four-week post-radiosurgery pelvic examinations revealed a decrease in size of the treated right labia majora mass to 1 cm with associated necrosis. Six-and eight-week post-cyberknife pelvic examinations showed a further decrease in size of the right labia majora mass to 0.5 cm, again with associated necrosis. Four weeks after completing cyberknife radiosurgery to the right labia majora mass, she underwent computed tomography-guided placement of six non-coplanar fiducials in the right pelvis in the region of the PET-positive 2 cm right external iliac lymph node. With the patient in the supine treatment position, the right external iliac lymph node clinical target volume of 6.6 cm 3 received 2400 cGy in three fractions of 800 cGy prescribed to the 80 percent isodose line with a conformality index of 1.9 to achieve 99.9 percent coverage. Treatment consisted of 105 non-coplanar 6MV photon beams shaped by a 25 mm collimator with source to axis distance ranging between 900 and 1000 millimeters. Elapsed treatment time was approximately 24 minutes and total estimated treatment delivery time was 65 minutes for each fraction. No significant skin, urinary, or gastrointestinal toxicities were documented during fractionated treatments.
At eight weeks follow-up after the first cyberknife treatment to the vulva, the patient noted right labia minor and clitoral hood pruritus and discomfort. Examination showed superficial desquamation of the right labia minor and clitoral hood and necrosis within the radiosurgical treatment field. Conservative clinical management was continued with recommendations for aggressive pelvic hygiene with aloe-containing emollient skin barrier and pentoxifylline (400 mg) three times daily with meals. After 16 weeks from her first and ten weeks after her second cyberknife radiosurgery, PET staging scans showed no visceral metastases, reduced hypermetabolic activity in the radiosurgically-targeted right external iliac lymph node, but persistent hypermetabolic activity in the vulva. Biopsy performed 16 weeks after completion of cyberknife radiosurgery to the right labia confirmed a new area of squamous cell carcinoma involving the right periurethral skin, clitoris, and left labia outside the initial radiosurgical field. She has elected palliative supportive care and remains alive.
Case 3:
A 86-year old gravida 3, para 3 female with comorbid cardiovascular disease was diagnosed with a stage III (T3N0M0) locally-advanced 3 × 3 cm pruritic posterior forchette vulvar lesion. Pathology confirmed an invasive squamous cell carcinoma of the vulva. Staging computed tomography scans demonstrated an irregular mass of the vulva not associated with groin lymph node or other visceral metastases. She then underwent three weekly cisplatin chemotherapy infusions (20, 30, and 40 mg/m 2 ) concurrent with pelvic (5400 cGy) and groin (3600 cGy) radiation. Afterwards, vulvectomy with bilateral groin lymphadenectomy was completed and pathology identified a 1.7 cm residual squamous cell carcinoma, tumor-free margins of 20 mm, and no groin metastases (0 of 12).
Six months after vulvectomy, she developed a biopsy-confirmed 2.5 cm invasive squamous cell carcinoma of the right labia minora. She desired non-surgical treatment and cy-berknife radiosurgery was performed with the patient in the supine treatment position. The right labia minora tumor volume of 25.0 cm 3 was treated to 2400 cGy in three fractions of 800 cGy prescribed to the 75 percent isodose line with a conformality index of 1.8 to achieve 97.2 percent coverage. Note that a non-targeted 2 cm area of the left labia majora was enclosed by the prescription 75 percent isodose line due to patient supine positioning. For treatment, 197 non-coplanar 6MV photon beams shaped by a 15 mm collimator were used with a source to axis distance ranging between 900 and 1000 millimeters. During radiosurgical treatment, fluoroscopic tracking verified that soft tissue markers remained positioned with no significant local or distant migration. Elapsed treatment time was approximately 72 minutes and total estimated treatment delivery time was 117 minutes for each fraction. Fractionated treatments were tolerated without significant skin, urinary, or gastrointestinal toxicities.
At two-and four-week follow-up after cyberknife radiosurgical treatment, she noted intense discomfort in the right pelvis associated with a malodorous vaginal discharge. Pelvic examinations showed necrosis of the 3 × 3 cm radiosurgically-targeted right labial minora lesion. Also, a new 2 × 2 cm left vulva ulceration was noted within the non-targeted left labia majora encompassed within the radiosurgical treatment field. Close supervision was continued with recommendations for aggressive pelvic hygiene with silvadene cream 1% topical application twice daily.
At eight-week follow-up, the treated necrotic right-sided lesion increased to 5 × 4 cm with elevated rolled borders. The associated 2 × 2 cm area of left vulvar ulceration was still present. She underwent surgical debridement with biopsies of the radiosurgically-targeted right-sided ulcerated lesion showing necrotic squamous cell carcinoma. Biopsy of the elevated rolled borders outside the radiosurgical field revealed viable invasive squamous cell carcinoma. Biopsy of the non-targeted left labia majora within the radiosurgical treatment field showed necrosis with no malignancy. After her surgical debridement, she elected palliative supportive care and remains alive.
Discussion
The use of radiation therapy for recurrent vulvar cancer after vulvectomy has two established roles. First, in unresectable or marginally resectable disease, results from primary surgical therapy are quite poor often resulting from second relapses or groin metastases (14-17). The goal of radiation therapy in this setting is to improve treatment outcomes by sterilizing recurrent vulvar and occult nodal disease. Second, in patients with disease requiring modified exenterative procedures, radiation provides a therapeutic means to preserve organ structure and function and to reduce psychosexual morbidity from altered pelvic cosmesis (18, 19) . In the previously radiated patient with unresectable or marginally resectable disease, re-irradiation has met with less than desirable outcomes (20, 21) . In an era of radiation dose delivery with potential submillimeter accuracy as offered by cyberknife radiosurgery, perhaps re-irradiation can be revisited.
A MEDLINE search of the English language literature using the terms vulvar cancer, recurrence, and radiosurgery revealed no published case series describing cyberknife radiosurgery for vulvar cancer. These three cases represent the first three women whose vulvar cancer recurrences, occurring after prior vulvar radiation, were treated by cyberknife radiosurgery.
Among these three women, cyberknife radiosurgery did not produce clinically significant toxicities over the fractionated course of therapy. At two-and four-week follow-up visits, all three women noted skin irritation and desquamating necrosis of the radiosurgical treatment field. Conservative topical cream or emollient treatment alleviated symptoms. There were no persistent urinary or gastrointestinal toxicities observed.
Although cyberknife radiosurgery sterilized known sites of vulvar cancer recurrence, all three patients developed progressive disease within three months of their cyberknife radiosurgery. It is difficult to reconcile successful treatment of cyberknife radiosurgery targeted recurrent lesions with each patient's progressive out-of-field disease. One might argue that the prescription radiation dose was not high enough.
Biological equivalent dose calculations using the linear quadratic dose model suggest that 2400 cGy in three fractions prescribed to the 75 percent isodose line is equivalent to 5760 cGy in 200 cGy dose fractionation. In clinical studies of radiation therapy alone for vulvar cancer, radiotherapeutic doses of 4500-5000 cGy have response rates of 45 to 60 percent (18, 22, 23) . Linear quadratic dose models suggest that 800 cGy radiation dose fractions produce high tumor and normal tissue cytotoxicity (24). So that consequential late effects to late-responding tissues such as normal connective tissue and muscle perhaps are avoided, the time interval between hypofractionated radiation doses should be sufficiently long to allow sublethal radiation-related DNA damage repair. It is customary to consider six-hour sublethal damage repair kinetics in normal tissues, although late-responding tissues may have longer repair half-times (24). Here, a twenty-four hour time interval between radiosurgical fractions was selected to mitigate consequential late effects in late-responding vulvar connective and muscle tissues.
Another argument for progression of disease outside the cyberknife radiosurgery target recognizes geographical miss, a term coined to describe parts of the treatment zone that has escaped radiation or been inadequately irradiated because the total tumor volume was not appreciated and in-sufficient margin was taken. To ensure targeting accuracy, orthogonal digitally reconstructed radiographs are obtained serially during the course of radiation dose delivery to confirm three-dimensional orientation of implanted soft tissue fiducial markers surrounding the vulvar cancer. Deviations of these real time radiographs as compared to pretreatment images by either computer-driven robot detection system (if tolerance parameters are met) or the therapist and physician are continually monitored. This may result in serial adjustments to the patient's alignment, and thus the target localization, within the treatment zone. Moreover, in these three cyberknife radiosurgery cases, radiation dose was prescribed to isodose lines covering contoured target volumes with high conformality. While eradicating visualized tumor, prescription therapy may have left untreated occult microscopic disease. Since each patient subsequently developed progressive disease in abutting vulvar tissue suggests that geographic miss due to insufficient irradiated margin may have been the prime reason for disease progression after treatment. Therefore, we suggest expanding the tumor target dimensions by 0.5 cm to create a planning target volume to assist in sterilizing occult microscopic disease surrounding the gross tumor volume. Utilizing a planning MRI in addition to the planning cyberknife CT scan may also help to improve target delineation. Of note, a comprehensive regimen of improved pelvic hygiene to reduce offending irritants such as stool may promote healing and reduce fistula rates.
Cyberknife radiosurgery represents a new radiotherapeutic modality for women having previous pelvic radiation and unresectable or marginally resectable primary or recurrent vulvar cancer. Additional study of treatment parameters and clinical outcomes including toxicity is planned.
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